[go: up one dir, main page]

CN1077887C - Preparation method of antihypertensive and antitumor compound - Google Patents

Preparation method of antihypertensive and antitumor compound Download PDF

Info

Publication number
CN1077887C
CN1077887C CN99116290A CN99116290A CN1077887C CN 1077887 C CN1077887 C CN 1077887C CN 99116290 A CN99116290 A CN 99116290A CN 99116290 A CN99116290 A CN 99116290A CN 1077887 C CN1077887 C CN 1077887C
Authority
CN
China
Prior art keywords
ethyl acetate
compounds
compound
culture
halorosellinia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN99116290A
Other languages
Chinese (zh)
Other versions
CN1243826A (en
Inventor
林永成
姜广策
周世宁
许东晖
王正廉
关利平
E·B·G·钟斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CN99116290A priority Critical patent/CN1077887C/en
Publication of CN1243826A publication Critical patent/CN1243826A/en
Application granted granted Critical
Publication of CN1077887C publication Critical patent/CN1077887C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及式A和式B的化合物及其制备方法和在制备降血压和抗肿瘤药物中的应用。

Figure 99116290

The present invention relates to compounds of formula A and formula B, their preparation methods and their use in preparing blood pressure lowering and anti-tumor drugs.

Figure 99116290

Description

降血压、抗肿瘤化合物的制备方法Preparation method of antihypertensive and antitumor compound

本发明涉及两种具有降血压、抗肿瘤活性的化合物及其制备方法,以及它们在制备药物中的应用。The invention relates to two compounds with hypotensive and antitumor activities, their preparation methods, and their application in the preparation of medicines.

自从1929年弗莱明从真菌中发现青霉素以来,真菌的代谢产物成为了药物的丰富来源,绝大多数临床应用的抗生素都来源于真菌和细菌,真菌的代谢产物还有其他的药用价值,如抗肿瘤,治疗心血管疾病,免疫调节剂,酶抑制剂等。由于海洋环境的特殊性,海洋真菌能提供陆生真菌无法提供的代谢产物。国际上已从海洋真菌中发现了一些结构独特的化合物,分别具有抗菌,抗病毒,抗肿瘤和神经心血管方面的活性。例如从Acremonium ehrysogenum产生的头孢菌素,已发展为一大类半合成抗生素的先导,广泛应用于临床,还有其他的一些例子见Kerstin Liberra的文章《Marine fungi a profile resource of biologically activenatural products?》[Pharmazie 50(1995)H.9:583-588],国际上这方面的研究从八十年代以来呈加速发展的趋势。Since Fleming discovered penicillin from fungi in 1929, fungal metabolites have become a rich source of drugs. Most clinically used antibiotics are derived from fungi and bacteria. Fungal metabolites have other medicinal values. Such as anti-tumor, treatment of cardiovascular diseases, immunomodulators, enzyme inhibitors, etc. Due to the particularity of the marine environment, marine fungi can provide metabolites that terrestrial fungi cannot provide. Some compounds with unique structures have been discovered from marine fungi internationally, which have antibacterial, antiviral, antitumor and neurocardiovascular activities. For example, cephalosporins produced from Acremonium ehrysogenum have been developed into a large class of semi-synthetic antibiotics and are widely used in clinical practice. For other examples, see the article "Marine fungi a profile resource of biologically active natural products?" by Kerstin Liberra. "[Pharmazie 50 (1995) H.9: 583-588], international research in this area has shown a trend of accelerated development since the 1980s.

本发明的目的在于提供一类新的具有潜在药用价值的化合物及其提取分离方法,以及它们在制备降血压、抗肿瘤药物中的用途。The purpose of the present invention is to provide a new class of compounds with potential medical value and their extraction and separation method, as well as their use in the preparation of antihypertensive and antitumor drugs.

真菌Halorosellinia oceanicum系从亚热带海洋生态环境中分离得到,其子囊果单个或成组排列,缺乏良好发育的子囊,在以燕麦琼脂为批培养基的培养皿中,接种4个星期后,菌落可长满培养基表面,生长初期,菌落呈白色,被散毛,紧贴于培养基,并呈不规则的环纹,有致密,完整的边缘,而后环纹有颜色逐渐加深,培养物的底面没有颜色。子囊果单个或数个并生,线状或环状,在新鲜培养物上呈革质,子囊中有8个孢子,子囊孢子单列,或在子囊顶部呈部分双列,为灰绿色或不透明的褐色,子囊孢子壁光滑,稍厚,无附着物或附生孢子,子囊孢子芽裂通常可在背侧清晰见到,直而明显。该属真菌的代谢产物研究还未见有报道。The fungus Halorosellinia oceanicum is isolated from the subtropical marine ecological environment. Its ascocarps are arranged singly or in groups and lack well-developed ascus. In a petri dish with oat agar as a batch medium, after 4 weeks of inoculation, the colony can grow The surface of the culture medium is full. In the initial stage of growth, the colony is white, covered with scattered hairs, and clings to the culture medium. It has irregular ring patterns with dense and complete edges, and then the color of the ring patterns gradually deepens. The bottom surface of the culture has no color. Ascocarps solitary or several side by side, linear or ring-shaped, leathery on fresh cultures, 8 spores in the ascus, ascospores in single row, or partly double row in the top of the ascus, gray-green or opaque Brown, ascospore wall smooth, slightly thick, without attachments or epispores, ascospore buds can usually be clearly seen on the back side, straight and obvious. There is no report on the metabolites of this genus of fungi.

发明人由南海海洋真菌Halorosellinia oceanicum 323的发酵培养物中提取分离到二种结构新颖的化合物,其结构是由苯乙胺与不规则取代二萜构成,这一结构是没有先例的。The inventor extracted and isolated two compounds with novel structures from the fermentation culture of the marine fungus Halorosellinia oceanicum 323 in the South China Sea. The structure is composed of phenethylamine and irregularly substituted diterpenes. This structure is unprecedented.

本发明化合物如下列式(A)和式(B)所示(以下分别简称为化合物A和B):

Figure C9911629000031
Compound of the present invention is shown in following formula (A) and formula (B) (hereinafter referred to as compound A and B respectively for short):
Figure C9911629000031

本发明化合物A和B可以从真菌Halorosellinia oceanicum 323的发酵液中提取分离而得到。The compounds A and B of the present invention can be obtained by extracting and separating from the fermentation broth of the fungus Halorosellinia oceanicum 323.

本发明所用的的真菌Halorosellinia oceanicum 323已保藏于中国典型培养物保藏中心(CCT,中国,武汉大学校内),保藏号为CCTCC No:99008,保藏日为1999年5月31日。The fungus Halorosellinia oceanicum 323 used in the present invention has been preserved in the China Center for Type Culture Collection (CCT, China, within the campus of Wuhan University), the preservation number is CCTCC No: 99008, and the preservation date is May 31, 1999.

制备本发明化合物A和B的方法包括以下步骤;The method for preparing compounds A and B of the present invention comprises the following steps;

a.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的种子培养:培养基成分按重量比为:葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、琼脂1-1.5、氯化钠3-5、水100,制成试管斜面,挑取菌株接入斜面,30-35℃培养5-7天;a. Seed culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: medium composition by weight: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, agar 1-1.5, sodium chloride 3-5 , water 100, make a test tube slant, pick the strains and insert them into the slant, and cultivate them at 30-35°C for 5-7 days;

b.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的发酵培养:发酵培养基成分按重量比为:葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、氯化钠3-5、水100、将斜面中培养好的菌株挑入发酵培养基,于室温25-35℃静置1-2月;b. Fermentation culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: The composition of the fermentation medium is: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, sodium chloride 3-5, water 100, Pick the cultured strains in the slope into the fermentation medium, and let it stand at room temperature 25-35°C for 1-2 months;

c.将上述培养好的发酵液过滤除去菌体;c. filtering the above-mentioned cultivated fermented liquid to remove the thallus;

d.将发酵液加热浓缩至原液体积的1/3-1/5,用乙酸乙酯萃取多次,浓缩乙酸乙酯萃取液,在硅胶柱中进行色谱分离,以乙酸乙酯∶石油醚=1%-100%为洗脱剂梯度洗脱;d. The fermented liquid is heated and concentrated to 1/3-1/5 of the volume of the stock solution, extracted several times with ethyl acetate, concentrated ethyl acetate extract, and chromatographically separated in a silica gel column, using ethyl acetate:petroleum ether= 1%-100% is gradient elution of eluent;

e.收集70%-90%的乙酸乙酯∶石油醚洗脱液,浓缩得白色针状结晶,得到A、B混合物,在甲醇中多次重结晶,分离A与B。e. Collect 70%-90% ethyl acetate:petroleum ether eluate and concentrate to obtain white needle crystals to obtain a mixture of A and B. Recrystallize multiple times in methanol to separate A and B.

动物实验表明,化合物A、B和异丙肾上腺素均能抑制回肠段的自动节律收缩,化合物A、B在终浓度为5×10-6-5×10-3mg/ml的剂量范围内,缓慢松弛平滑肌,至15min时完全松弛,并且平滑肌的松弛可持续2.5小时(每间隔20分钟冲洗一次),而异丙肾上腺素松弛作用快,冲洗后约20分钟可恢复,异丙肾上腺素的终浓度为5×10-5mg/ml。Animal experiments showed that compounds A, B and isoproterenol could all inhibit the automatic rhythmic contraction of the ileum, and the final concentrations of compounds A and B were within the dose range of 5×10 -6 -5×10 -3 mg/ml, Slowly relax the smooth muscle until it is completely relaxed in 15 minutes, and the relaxation of the smooth muscle can last for 2.5 hours (washing once every 20 minutes), while the relaxation effect of isoproterenol is fast, and it can be recovered in about 20 minutes after washing. The concentration is 5×10 -5 mg/ml.

本发明化合物对兔血管平滑肌的作用,在终浓度为5×10-6-5×10-3mg/ml,能抑制肾上腺素引起的兔主动脉血管平滑肌的收缩,浓度大于5×10-3mg/ml时直接松弛兔主动脉血管平滑肌。The effect of the compound of the present invention on rabbit vascular smooth muscle is at a final concentration of 5×10 -6 -5×10 -3 mg/ml, and it can inhibit the contraction of rabbit aortic vascular smooth muscle caused by adrenaline, and the concentration is greater than 5×10 -3 At mg/ml, it directly relaxes the smooth muscle of rabbit aorta.

本发明化合物剂量为0.2mg/kg在麻醉大鼠试验中具有明显的降压效果,维持时间2小时仍未恢复。The dose of the compound of the present invention is 0.2 mg/kg, which has obvious antihypertensive effect in the test of anesthetized rats, and has not recovered after 2 hours.

本发明化合物A与B均能抑制肿瘤细胞株的生长,在以口底癌细胞株为靶细胞的MTT还原法检测抗肿瘤活性试验中,化合物A的半数致死量IC50为124μg/ml,化合物B的IC50为129μg/ml。Both compounds A and B of the present invention can inhibit the growth of tumor cell lines. In the MTT reduction method detection anti-tumor activity test using the mouth floor cancer cell line as the target cell, the IC50 of the compound A is 124 μg/ml, and the compound The IC50 of B was 129 μg/ml.

上述结果表明,化合物A、B具良好的松弛平滑肌的作用,且持续时间长于现有药物异丙肾上腺素,化合物有A、B具有明显的降压效果,维持时间2小时仍未恢复。同时化合物A与B均能有效抑制肿瘤细胞株的生长。所以,本发明化合物A或/和B可用于制备降血压和抗肿瘤药物。The above results show that compounds A and B have good smooth muscle relaxation effects, and the duration is longer than that of the existing drug isoproterenol. Compounds A and B have obvious antihypertensive effects, which have not recovered after 2 hours. At the same time, both compounds A and B can effectively inhibit the growth of tumor cell lines. Therefore, the compound A or/and B of the present invention can be used in the preparation of antihypertensive and antitumor drugs.

下面结合实施例对本发明作进一步说明。The present invention will be further described below in conjunction with embodiment.

实施例1Example 1

化合物A、B的分离制备方法The separation and preparation method of compound A and B

a.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的种子培养:培养基成分按重量比为:葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、琼脂1-1.5、氯化钠3-5、水100,制成试管斜面,挑取菌株接入斜面, 30-35℃培养5-7天;a. Seed culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: medium composition by weight: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, agar 1-1.5, sodium chloride 3-5 , water 100, make a test tube slope, pick the strains into the slope, and cultivate at 30-35°C for 5-7 days;

b.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的发酵培养:发酵培养基成分按重量比为∶葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、氯化钠3-5、水100、将斜面中培养好的菌株挑入发酵培养基,于室温25-35℃静置1-2月;b. Fermentation culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: The components of the fermentation medium are: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, sodium chloride 3-5, water 100, Pick the cultured strains in the slope into the fermentation medium, and let it stand at room temperature 25-35°C for 1-2 months;

c.将上述培养好的发酵液过滤除去菌体;c. filtering the above-mentioned cultivated fermented liquid to remove the thallus;

d.将发酵液加热浓缩至原液体积的1/3-1/5,用乙酸乙酯萃取多次,浓缩乙酸乙酯萃取液,在硅胶柱中进行色谱分离,以乙酸乙酯∶石油醚=1%-100%为洗脱剂梯度洗脱;d. The fermented liquid is heated and concentrated to 1/3-1/5 of the volume of the stock solution, extracted several times with ethyl acetate, concentrated ethyl acetate extract, and chromatographically separated in a silica gel column, using ethyl acetate:petroleum ether= 1%-100% is gradient elution of eluent;

e.收集70%-90%的乙酸乙酯∶石油醚洗脱液,浓缩得白色针状结晶,得到A、B混合物,在甲醇中多次重结晶,分离A与B。e. Collect 70%-90% ethyl acetate:petroleum ether eluate and concentrate to obtain white needle crystals to obtain a mixture of A and B. Recrystallize multiple times in methanol to separate A and B.

A和B均为白色针状结晶,A熔点280℃(分解),B熔点274℃(分解)。Both A and B are white needle crystals, the melting point of A is 280°C (decomposition), and the melting point of B is 274°C (decomposition).

化合物A的试验数据:元素分析:C30H37NO6(A与B相同)%          碳       氢      氮A实测值    70.86    7.53    2.25B实测值    71.03    7.58    2.37计算值     71.01    7.30    2.76MS(FAB)m/z:509,490,479,448,430,412,402,388,357,348,289,265,254,172,165,91,77。IR(KBr)cm-1:3416,3233,3128,2973,2974,2860,1743,1693,1454,1370,1271,1229,1046,1011,962,906,779,744,702。UV(CHCl3)λmax nm:238(ε12845),260(ε11379),281(ε7706)1HNMR(CDCl3,TMS)ppm:7.32(t,8,8Hz,2H),7.26(t,8,8Hz,1H),7.14(d,8Hz,2H)),6.11(dd,2,15.5Hz,1H),5.72(bs,1H),5.69(dd,10,15.5Hz,1H),3.24(bs,1H),2.85(t,10,10Hz,1H),2.81(dd,5,13.5Hz,1H),2.74(dq,7,12.5Hz,1H),2.70(d,3.5,7Hz,1H),2.68(dd,9.5.13.5Hz,1H),2.51(ddd,10.5,12.5,13Hz,1H),2.15(dd,3.5,5Hz,1H),2.27(s,3H),1.51(s,3H),1.21(d,6.5Hz,3H),0.94(d,6.5Hz,3H),1.92(br,2H)13C-NMR(CDCl3):C   210.24,173.73,169.66,147.5,137.16,77.67,53.28CH  134.04,132.25,130.56,127.52,127.02,69.77,77.10,53.56,49.85,46.91,42.27,32.60,129.07×2,128.88×2CH2114.41,45.18,37.68CH324.12,20.79,19.35,13.6Experimental data of compound A: Elemental analysis: C 30 H 37 NO 6 (A and B are the same) % Hydrocarbon nitrogen A measured value 70.86 7.53 2.25B measured value 71.03 7.58 2.37 calculated value 71.01 7.30 2.76MS (FAB) m/z: 509, 490, 479, 448, 430, 412, 402, 388, 357, 348, 289, 265, 254, 172, 165, 91, 77. IR(KBr)cm -1 : 3416, 3233, 3128, 2973, 2974, 2860, 1743, 1693, 1454, 1370, 1271, 1229, 1046, 1011, 962, 906, 779, 744, 702. UV (CHCl 3 ) λmax nm: 238 (ε12845), 260 (ε11379), 281 (ε7706) 1 HNMR (CDCl 3 , TMS) ppm: 7.32 (t, 8, 8Hz, 2H), 7.26 (t, 8, 8Hz , 1H), 7.14(d, 8Hz, 2H)), 6.11(dd, 2, 15.5Hz, 1H), 5.72(bs, 1H), 5.69(dd, 10, 15.5Hz, 1H), 3.24(bs, 1H ), 2.85(t, 10, 10Hz, 1H), 2.81(dd, 5, 13.5Hz, 1H), 2.74(dq, 7, 12.5Hz, 1H), 2.70(d, 3.5, 7Hz, 1H), 2.68( dd, 9.5.13.5Hz, 1H), 2.51(ddd, 10.5, 12.5, 13Hz, 1H), 2.15(dd, 3.5, 5Hz, 1H), 2.27(s, 3H), 1.51(s, 3H), 1.21( d, 6.5Hz, 3H), 0.94(d, 6.5Hz, 3H), 1.92(br, 2H) 13 C-NMR (CDCl 3 ): C 210.24, 173.73, 169.66, 147.5, 137.16, 77.67, 53.28CH 134.04, 132.25, 130.56, 127.52, 127.02, 69.77, 77.10, 53.56, 49.85, 46.91, 42.27, 32.60, 129.07×2, 128.88×2 CH 2 114.41, 45.18, 37.68 CH 3 26.12, 190.79,

 化合物B的试验数据:NS(FAB)m/z:508,490,479,60,448,43,412,48,20,89,79,19,165,136,120,107,9177,65,51IR(KBr)cm-1:3416,3198,3121,2973,2924,2853,1743,1700,1461,1377,1236,1046,1011,962UV(CHCl3)λmax nm:238(ε6457),281(ε2660),301(ε1875),328(ε1640)1HNMR(CDCl3,TMS)ppm:7.32(t,7,7Hz,2H),7.25(t,7,7Hz,1H),7.17(d,7Hz,2H),6.01(dd,2,15.5,1H),5.90(t,2,2Hz,1H),5.89(dd,15.5,10.5Hz,1H),5.34(ddd,15.5,10.5,5.5H2,1H),5.16(dd,2,15.5Hz,1H),3.78(d,10Hz,1H),3.34(dd,7.5,6.5Hz,1H),2.96(dd,7.5,14Hz,2H),2.74(dq,7,12.5Hz,1H),2.471(bs,1H),2.26(s),1.70(s,3H),1.51(s,3H),1.46(s,3H),1.20(d,7Hz,3H).13C-NMR(CDCl3)ppm:C   210.00,174.40,169.60,137.60,131.40,126.30,77.86,52.64,CH  134.11,131.99,131.0,128.35,127.02,75.02,68.10,60.28,50.46,49.84,42.44,129.10×2,128.92×2.CH244.79.37.64CH324.32,2.79,19.36,17.17,13.84Test data of compound B: NS(FAB) m/z: 508, 490, 479, 60, 448, 43, 412, 48, 20, 89, 79, 19, 165, 136, 120, 107, 9177, 65, 51IR(KBr)cm -1 : 3416, 3198, 3121, 2973, 2924, 2853, 1743, 1700, 1461, 1377, 1236, 1046, 1011, 962UV(CHCl 3 ) λmax nm: 238(ε6457), 281(ε2660 ), 301 (ε1875), 328 (ε1640) 1 HNMR (CDCl 3 , TMS) ppm: 7.32 (t, 7, 7Hz, 2H), 7.25 (t, 7, 7Hz, 1H), 7.17 (d, 7Hz, 2H ), 6.01(dd, 2, 15.5, 1H), 5.90(t, 2, 2Hz, 1H), 5.89(dd, 15.5, 10.5Hz, 1H), 5.34(ddd, 15.5, 10.5, 5.5H2, 1H), 5.16(dd, 2, 15.5Hz, 1H), 3.78(d, 10Hz, 1H), 3.34(dd, 7.5, 6.5Hz, 1H), 2.96(dd, 7.5, 14Hz, 2H), 2.74(dq, 7, 12.5Hz, 1H), 2.471(bs, 1H), 2.26(s), 1.70(s, 3H), 1.51(s, 3H), 1.46(s, 3H), 1.20(d, 7Hz, 3H). 13C -NMR (CDCl 3 ) ppm: C 210.00, 174.40, 169.60, 137.60, 131.40, 126.30, 77.86, 52.64, CH 134.11, 131.99, 131.0, 128.35, 127.02, 75.02, 68.10, 60.461, 42.9, 50.8 2, 128.92×2.CH 2 44.79.37.64CH 3 24.32, 2.79, 19.36, 17.17, 13.84

实施例2Example 2

化合物A、B对豚鼠回肠平滑肌的作用Effects of Compounds A and B on Guinea Pig Ileum Smooth Muscle

a.分别精确称取化合物A、B各15mg,先用8滴二甲亚砜溶解,然后缓慢加入双蒸水配制的生理盐水定容10ml,配制成1.5mg/ml的浓度。a. Accurately weigh 15 mg each of compounds A and B, dissolve them with 8 drops of dimethyl sulfoxide, then slowly add 10 ml of normal saline prepared with double distilled water to a concentration of 1.5 mg/ml.

b.豚鼠击昏剖取回肠,用预冷的台氏营养液(1000mlH2O,NaCl 8g,KCl 0.2g,MgCl20.1g,NaH2PO4.2H2O 0.05g,NaHCO3 1g,CaCl2 0.2g,葡萄糖1g,pH7.4)冲洗肠管中的食物残渣,然后剪成3厘米的长度,两端用蛙心夹夹住,置于灌流浴槽中,下端蛙心夹固定于浴槽底部,上端蛙心夹用线连接二道生理记录仪(成都仪器厂,LMS-2B)的拉力换能器,回肠段的自动节律收缩被记录下来,浴槽中台氏营养液恒温35℃,通入纯氧,回肠段挂上去时施加1g的拉力,平衡40min开始(每20min换台氏营养液一次)。先记录一段回肠正常收缩的曲线,然后分别加入和阳性对照药异丙肾上腺素。b. The guinea pig was stunned and the ileum was dissected, and the ileum was taken with pre-cooled Tyrode nutrient solution (1000mlH 2 O, NaCl 8g, KCl 0.2g, MgCl 2 0.1g, NaH 2 PO 4 .2H 2 O 0.05g, NaHCO 3 1g, CaCl 2 0.2g, glucose 1g, pH 7.4) wash the food residue in the intestine, then cut it into a length of 3 cm, clamp both ends with frog heart clips, place in the perfusion bath, and fix the frog heart clip at the bottom of the bath , the upper end of the frog heart clip is connected to the tension transducer of the second physiological recorder (Chengdu Instrument Factory, LMS-2B) with a line, and the automatic rhythmic contraction of the ileum is recorded. Pure oxygen, when the ileum is hung up, apply a pulling force of 1g, and start to balance for 40 minutes (change Tyrode's nutrient solution every 20 minutes). First record a section of normal contraction curve of the ileum, and then add isoproterenol and the positive control drug respectively.

试验结果如下:The test results are as follows:

化合物A、B和异丙肾上腺素均能抑制回肠段的自动节律收缩,化合物A、B在终浓度为5×10-6-5×10-3mg/ml的剂量范围内,缓慢松弛平滑肌,至15min时完全松弛,并且平滑肌的松弛可持续2.5小时(每间隔20分钟冲洗一次),而异丙肾上腺素松弛作用快,冲洗后约20分钟可恢复,异丙肾上腺素的终浓度为5×10-5mg/ml。Compounds A, B and isoproterenol can all inhibit the automatic rhythmic contraction of the ileum. Compounds A and B slowly relax smooth muscle in the dose range of 5×10 -6 -5×10 -3 mg/ml in the final concentration. It relaxes completely at 15 minutes, and the relaxation of smooth muscle can last for 2.5 hours (washing every 20 minutes), while the relaxation effect of isoproterenol is fast, and it can be restored in about 20 minutes after washing. The final concentration of isoproterenol is 5× 10 -5 mg/ml.

结果表明化合物A、B具有良好的松弛平滑肌的作用,且持续时间长于现有药物异丙肾上腺素。The results show that compounds A and B have a good smooth muscle relaxation effect, and the duration is longer than that of the existing drug isoproterenol.

实施例3Example 3

化合物A、B对兔主动脉条的作用Effects of Compounds A and B on Rabbit Aortic Strips

新西兰大白兔一只,去头致昏,开胸,迅速取出其胸主动脉,放入预冷通氧气的Lock氏液(1000ml H2O,NaCl 9g,KCl 0.35g,MgSO4·7H2O 0.35g,KH2PO4 0.16g,NaHCO31g)中,快速洗尽血污,然后小心剪去血管外的结蹄组织,与管纵径成45度角剪成宽2-3mm动脉条供试验用。One New Zealand white rabbit was decapitated, and the chest was opened. The thoracic aorta was quickly taken out, and put into pre-cooled Lock's solution (1000ml H 2 O, NaCl 9g, KCl 0.35g, MgSO 4 7H 2 O 0.35g, KH 2 PO 4 0.16g, NaHCO 3 1g), quickly wash away the blood, then carefully cut off the hoof tissue outside the blood vessel, and cut it into a 2-3mm wide artery strip at an angle of 45 degrees to the longitudinal diameter of the tube for testing use.

取2cm左右长度的动脉条,两端用蛙心夹夹住,置于恒温38℃的灌流浴槽中,浴液中通入氧气,下端蛙心夹固定于浴槽底部,上端蛙心夹用线连接拉力换能器,用二道生理记录仪(成都仪器厂,LMS-2B)记录血管条的收缩力。动脉条在灌流浴槽中,平衡80min开始试验,此间每隔20分钟换一次Lock氏液,加入浓度5×10-3mg/ml的化合物A,可松弛血管,加入终浓度1.6×10-6mg/ml的肾上腺素,记录血管条的收缩曲线,待收缩高度不再增加时,冲去,共冲洗3次,40分钟后待血管条基线恢复时,先加入5×10-4mg/ml的化合物A作用10分钟,可见在此浓度下,化合物A无直接松弛血管平滑肌的作用,然后再加入终浓度1.6×10-6mg/ml的肾上腺素,可见此次加入的肾上腺素只能使血管条的收缩增加到原来的1/3,化合物B的结果与A类似。Take an artery strip with a length of about 2 cm, clamp both ends with frog heart clips, place it in a perfusion bath with a constant temperature of 38°C, and inject oxygen into the bath liquid, fix the lower end of the frog heart clip to the bottom of the bath, and connect the upper end of the frog heart clip with a wire Tension transducer, and the contraction force of the blood vessel strips were recorded with a two-channel physiological recorder (Chengdu Instrument Factory, LMS-2B). The arterial strips were placed in the perfusion bath, equilibrated for 80 minutes to start the test, during which the Lock’s solution was changed every 20 minutes, and compound A with a concentration of 5×10 -3 mg/ml was added to relax the blood vessels, and the final concentration was 1.6×10 -6 mg /ml of adrenaline, record the contraction curve of the blood vessel strip, and wash it away when the contraction height no longer increases, and wash it 3 times in total. After 40 minutes, when the baseline of the blood vessel strip returns, first add 5×10 -4 mg/ml Compound A acts for 10 minutes. It can be seen that at this concentration, Compound A has no direct effect on relaxing vascular smooth muscle. Then add epinephrine with a final concentration of 1.6×10 -6 mg/ml. It can be seen that the added adrenaline can only relax blood vessels. The shrinkage of the bar was increased to 1/3 of the original, and the results of compound B were similar to A.

试验结果表明化合物A在浓度大于5×10-3mg/ml时,直接松弛血管,低于此浓度时,不直接松弛血管平滑肌,但可使肾上腺素对血管收缩力降低。化合物B的结果与A类似。The test results show that compound A directly relaxes blood vessels when the concentration is greater than 5×10 -3 mg/ml, and does not directly relax vascular smooth muscle when the concentration is lower than this concentration, but can reduce the contractility of epinephrine on blood vessels. The results for compound B were similar to A.

实施例4Example 4

化合物A、B的降血压作用Antihypertensive effect of compounds A and B

SD系大鼠用40mg/ml的戊巴比妥钠麻醉,背位固定于试验台上,剪去颈部毛,切开皮肤,分离左颈总动脉,近心端用动脉夹夹住,远心端用绒线扎,用眼科剪在近绒线处剪V形小口,插入充满肝素生理盐水的动脉插管,动脉插管与血压换能器相连,血压换能器相连接入计算机控制的三通道生理药理记录系统,分离大鼠的右股静脉并插管,供注射药物用。待血压稳定后(即血压收缩曲线平稳后)开始试验。分别注射剂量为0.2mg/kg的化合物A,可见有显著的降压作用。SD rats were anesthetized with 40 mg/ml pentobarbital sodium, fixed on the test bench in the dorsal position, cut off the neck hair, cut the skin, separated the left common carotid artery, clamped the proximal end with an arterial clip, and The end of the heart is tied with woolen thread, and a small V-shaped opening is cut near the woolen thread with ophthalmological scissors, and an arterial cannula filled with heparin saline is inserted. The arterial cannula is connected to a blood pressure transducer, and the blood pressure transducer is connected to a computer-controlled three-channel Physiological and pharmacological recording system, the right femoral vein of rats was isolated and cannulated for drug injection. After the blood pressure is stabilized (that is, after the blood pressure contraction curve is stable), the test is started. Compound A was injected at a dose of 0.2 mg/kg, and it can be seen that there is a significant antihypertensive effect.

试验结果为:时间(分钟)     0     5    15    60平均动脉压(Kpa)13.8  8.7  9.0   9.5化合物8的结果与A类似。The test results are: time (minutes) 0 5 15 60 mean arterial pressure (Kpa) 13.8 8.7 9.0 9.5 The results of compound 8 are similar to those of A.

结果表明化合物A、B具有明显而持久的降血压效果。The results showed that compounds A and B had obvious and lasting blood pressure lowering effects.

实施例5Example 5

MTT还原法检测化合物A、B抗肿瘤活性试验Anti-tumor activity test of compounds A and B detected by MTT reduction method

1.材料:1. Materials:

1.1四脞盐(MTT):用0.01mol/L的磷酸盐缓冲液(PBS)溶解MTT(3-(4,5-dimethythiazol-z-yl)2,5-diphenytetrazolium bromide,SIGMA)终浓度5mg/ml,过滤除菌,分装后4℃避光保存。1.1 Tetrazolium salt (MTT): Dissolve MTT (3-(4,5-dimethylthiazol-z-yl)2,5-diphenytetrazolium bromide, SIGMA) with 0.01mol/L phosphate buffered saline (PBS) at a final concentration of 5mg/L ml, sterilized by filtration, and stored in the dark at 4°C after aliquoting.

1.2MTT裂解液的配制:80g的十二烷基磺酸钠(SDS,华病生物工程公司)溶解在200ml的N-N-二甲基甲酰胺(北京化工厂)中,水浴加热助溶,加入200ml蒸馏水,用80%乙酸与1N盐酸(1∶1)混合调pH至4.7。1.2 Preparation of MTT lysate: Dissolve 80g of sodium dodecylsulfonate (SDS, Huabing Bioengineering Co., Ltd.) in 200ml of N-N-dimethylformamide (Beijing Chemical Plant), heat in a water bath to aid dissolution, add 200ml Distilled water, mixed with 80% acetic acid and 1N hydrochloric acid (1:1) to adjust the pH to 4.7.

1.3靶细胞的制备:KBS细胞的复苏与培养1.3 Preparation of target cells: recovery and culture of KBS cells

a.从液氮罐中取出KBS细胞的冻存管,迅速置入37℃水浴中,不停摇动使之迅速溶化,无菌操作移入离心管中;a. Take out the cryopreservation tube of KBS cells from the liquid nitrogen tank, quickly place it in a 37°C water bath, shake it constantly to dissolve it quickly, and transfer it into a centrifuge tube aseptically;

b.加全培养液至10ml,1000rpm离心5s,弃上清;b. Add the whole culture medium to 10ml, centrifuge at 1000rpm for 5s, and discard the supernatant;

c.重复以上操作一次;c. Repeat the above operation once;

d.以全培养液吹打使细胞混匀后移入培养瓶中,5%CO2·37℃培养;d. Pipette the cells with the whole culture solution to mix the cells, then transfer them to a culture bottle, and culture at 5% CO 2 at 37°C;

e.观察细胞生长情况,及时更换培养液,分瓶。e. Observe the growth of the cells, replace the culture medium in time, and divide the bottles.

1.4 KBS细胞计数、96孔板准备1.4 KBS cell counting, 96-well plate preparation

a.选取对数生长期细胞,胰酶消化,全培养终止,移入离心管中,加全培至10ml;a. Select the cells in the logarithmic growth phase, trypsinize, terminate the whole culture, transfer to a centrifuge tube, add whole culture to 10ml;

b.取一滴滴入计数板一侧凹槽中,显微镜下计数四大格的细胞总数、除以4、乘104,即为每毫升培养液所含细胞数;b. Take one drop and drop it into the groove on one side of the counting plate, count the total number of cells in the four grids under the microscope, divide by 4, and multiply by 10 4 , which is the number of cells contained in each ml of culture medium;

c.调整细胞数至1×105ml;c. Adjust the number of cells to 1×10 5 ml;

d.96孔板置超镜台内在紫外线下照射4hr,距离30cm以内。d. Put the 96-well plate in the super mirror stage and irradiate it under ultraviolet light for 4 hours, within a distance of 30cm.

1.5化合物A与B的配制:取一定量的化合物A、B加入到全培中,调整浓度为500μg/ml,超声乳化,过滤除菌,4℃保存。1.5 Preparation of Compounds A and B: Add a certain amount of Compounds A and B to the whole culture, adjust the concentration to 500 μg/ml, ultrasonically emulsify, filter and sterilize, and store at 4°C.

1.6试验方法1.6 Test method

a.96孔板各孔加入KBS细胞180μl(1×105/ml),5%CO2、37℃培养4hr。a. 180 μl of KBS cells (1×10 5 /ml) were added to each well of a 96-well plate, and cultured at 37° C. for 4 hr in 5% CO 2 .

b.加入不同浓度受试对象各20pl,对照加全培2pl,继续培养48hr。b. Add 20 pl of each test subject at different concentrations, add 2 pl of whole culture to the control, and continue to cultivate for 48 hours.

c.每孔去除培养液100μl,加入MTT(5mg/ml各10μl,继续培养4hr。c. Remove 100 μl of culture solution from each well, add 10 μl of MTT (5 mg/ml each), and continue culturing for 4 hr.

d.每孔加入MTT裂解液100μl,轻轻振荡5-10min,使颗粒溶解,过夜。d. Add 100 μl of MTT lysate to each well, and shake gently for 5-10 minutes to dissolve the particles overnight.

e.酶联免疫仪570nm下测定各孔OD值。e. Measure the OD value of each well with an enzyme-linked immunosorbent analyzer at 570 nm.

f.计算抑制率:f. Calculate the inhibition rate:

肿瘤细胞杀伤率%=(对照组测定的平均OD值-加药组测定的平均OD值)/对照组测定的平均OD值×100%。Tumor cell killing rate%=(average OD value determined by the control group-average OD value determined by the drug-dosed group)/average OD value determined by the control group×100%.

g.以抑制率对药物浓度的对数作图,求得IC50值。g. Plot the logarithm of the inhibitory rate against the drug concentration to obtain the IC 50 value.

以lgc为横坐标,抑制率为纵坐标,求得IC50值。Take lgc as the abscissa and the inhibition rate as the ordinate to obtain the IC 50 value.

1.7结果1.7 Results

试验发现化合物A、B均能抑制KBS细胞株生长,其中A的IC50值为124μg/ml;B的IC50值为124μg/ml。It was found that both compounds A and B could inhibit the growth of KBS cell line, and the IC 50 value of A was 124 μg/ml; the IC 50 value of B was 124 μg/ml.

Claims (1)

1.下述结构式A和B的化合物的制备方法,
Figure C9911629000021
其特征是该方法包括以下步骤:
1. the preparation method of the compound of following structural formula A and B,
Figure C9911629000021
It is characterized in that the method comprises the following steps:
a.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的种子培养:培养基成分按重量比为:葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、琼脂1-1.5、氯化钠3-5、水100,制成试管斜面,挑取菌株接入斜面,30-35℃培养5-7天;a. Seed culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: medium composition by weight: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, agar 1-1.5, sodium chloride 3-5 , water 100, make a test tube slant, pick the strains and insert them into the slant, and cultivate them at 30-35°C for 5-7 days; b.真菌Halorosellinia oceanicum 323 CCTCC No:M99008的发酵培养:发酵培养基成分按重量比为:葡萄糖0.5-1.5、酵母提取物0.05-0.15、蛋白胨0.1-0.3、氯化钠3-5、水100、将斜面中培养好的菌株挑入发酵培养基,于室温25-35℃静置1-2月;b. Fermentation culture of the fungus Halorosellinia oceanicum 323 CCTCC No: M99008: The composition of the fermentation medium is: glucose 0.5-1.5, yeast extract 0.05-0.15, peptone 0.1-0.3, sodium chloride 3-5, water 100, Pick the cultured strains in the slope into the fermentation medium, and let it stand at room temperature 25-35°C for 1-2 months; c.将上述培养好的发酵液过滤除去菌体;c. filtering the above-mentioned cultivated fermented liquid to remove the thallus; d.将发酵液加热浓缩至原液体积的1/3-1/5,用乙酸乙酯萃取多次,浓缩乙酸乙酯萃取液,在硅胶柱中进行色谱分离,以乙酸乙酯∶石油醚=1%-100%为洗脱剂梯度洗脱;d. The fermented liquid is heated and concentrated to 1/3-1/5 of the volume of the stock solution, extracted several times with ethyl acetate, concentrated ethyl acetate extract, and chromatographically separated in a silica gel column, using ethyl acetate:petroleum ether= 1%-100% is gradient elution of eluent; e.收集70%-90%的乙酸乙酯∶石油醚洗脱液,浓缩得白色针状结晶,得到A、B混合物,在甲醇中多次重结晶,分离A与B。e. Collect 70%-90% ethyl acetate:petroleum ether eluate and concentrate to obtain white needle crystals to obtain a mixture of A and B. Recrystallize multiple times in methanol to separate A and B.
CN99116290A 1999-07-16 1999-07-16 Preparation method of antihypertensive and antitumor compound Expired - Fee Related CN1077887C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN99116290A CN1077887C (en) 1999-07-16 1999-07-16 Preparation method of antihypertensive and antitumor compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN99116290A CN1077887C (en) 1999-07-16 1999-07-16 Preparation method of antihypertensive and antitumor compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB011225890A Division CN1141094C (en) 1999-07-16 1999-07-16 Medicinal use of hypotensive and anti-tumour compound

Publications (2)

Publication Number Publication Date
CN1243826A CN1243826A (en) 2000-02-09
CN1077887C true CN1077887C (en) 2002-01-16

Family

ID=5279124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99116290A Expired - Fee Related CN1077887C (en) 1999-07-16 1999-07-16 Preparation method of antihypertensive and antitumor compound

Country Status (1)

Country Link
CN (1) CN1077887C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003289618A1 (en) * 2003-10-21 2005-05-05 Sun Yat-Sen University A compound, the preparation and the use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041205A1 (en) * 1997-03-18 1998-09-24 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
WO1998041205A1 (en) * 1997-03-18 1998-09-24 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis

Also Published As

Publication number Publication date
CN1243826A (en) 2000-02-09

Similar Documents

Publication Publication Date Title
JP5907931B2 (en) Thiacomycin production
CN108753627B (en) A marine Aspergillus-derived xanthraquinone compound and its preparation method and application in the preparation of antitumor agent
JPH08838B2 (en) New cyclosporins
CN108660082B (en) Marine aspergillus derived oxaanthraquinone compound, preparation method thereof and application thereof in preparation of antibacterial agent
CN1074937A (en) 4, the preparation of 5-dihydro geldanamycin and quinhydrones thereof and purposes
CN115039638B (en) Resin ganoderma lucidum strain H63 and application thereof
Chen et al. Streptopyrazinones A− D, rare metabolites from marine-derived Streptomyces sp. ZZ446
JP2012504559A (en) Epothilone glycoside compounds and their active ingredients and their applications
CN102816221B (en) Chicken E. tenella MA1 (EtMA1) gene, vector, recombinant strain, EtMA1 protein, EtMA1-Outside domain, and use of the EtMA1 protein and the EtMA1-Outside domain
CN1077887C (en) Preparation method of antihypertensive and antitumor compound
RU2482130C2 (en) Cyclic compound and salt thereof
DE60029084T2 (en) NEW DEPSIPEPTID CONNECTION
CN102002081B (en) 9-O-beta-D-glucosyl nandinine as well as preparation method and application thereof
US20020114794A1 (en) Staphylococcus aureus culture and preparation thereof
CN1141094C (en) Medicinal use of hypotensive and anti-tumour compound
US7375230B2 (en) Fermentation and purification of migrastatin and analog
KR20170076075A (en) Cordyceps Militaris and Method for Cultivating thereof
JP2002542258A (en) Antifungal substance isolated from Pseudomonas syringae
CN112159785B (en) Alteromonas mellea E6 and application thereof
US6660263B2 (en) Oocydin and methods of use for protection of plants from Oomyocyte pathogens
CN1212387C (en) Fine rod bundle spore SX-1 separated and cultured from cordyceps and its saparation, culture process and use
CN110330549A (en) Cyclic peptide emericellamide G and preparation method thereof and preparing the application in enzyme inhibitor
DE69711612T2 (en) CYCLIC HEPTAPEPTIDE DERIVATIVE OF THE COLONIAL ASCIDIANS, LISSOCLINUM SP
CN113185580B (en) A cyclic peptide compound derived from endophytic fungi of Artemisia annua and its application as an anti-tumor drug
JP2646707B2 (en) Novel compounds WF2015A and B, process for their preparation and compositions containing them

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee